AbCellera Biologics Inc. - stock earnings
ABCL Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -47.2 million USD | 9.2 million USD |
| 2023Q3 | -28.6 million USD | 6.6 million USD |
| 2023Q2 | -30.5 million USD | 10.1 million USD |
| 2023Q1 | -40.1 million USD | 12.2 million USD |
| 2022Q4 | -29.9 million USD | 21.5 million USD |
| 2022Q3 | 26.6 million USD | 101.4 million USD |
| 2022Q2 | -6.8 million USD | 45.9 million USD |
| 2022Q1 | 168.6 million USD | 316.6 million USD |
| 2021Q4 | 59.9 million USD | 139.3 million USD |
| 2021Q3 | -21.4 million USD | 5.5 million USD |
| 2021Q2 | -2.3 million USD | 27.6 million USD |
| 2021Q1 | 117.2 million USD | 202.7 million USD |
| 2020Q4 | 117.0 million USD | 207.9 million USD |
| 2020Q3 | -2.7 million USD | 9.4 million USD |
| 2020Q2 | 6.7 million USD | 11.2 million USD |
| 2020Q1 | -2.1 million USD | 4.7 million USD |
| 2019Q4 | -1.6 million USD | 3.2 million USD |
ABCL Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -146.4 million USD | 38.0 million USD |
| 2022 | 158.5 million USD | 485.4 million USD |
| 2021 | -2.2 million USD | 11.6 million USD |
| 2020 | 118.9 million USD | 233.2 million USD |
| 2019 | -2.4 million USD | 11.6 million USD |
| 2018 | 309000 USD | 8.8 million USD |
ABCL
Price: $4.03
52 week price:
Earnings Per Share: -0.51 USD
P/E Ratio: -11.16
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 1.3 million
Market Capitalization: 1.3 billion